

BioLeap Strengthens its Board of Directors

February 3, 2009

BioLeap LLC, a global leader in predictive drug discovery, is pleased to announce that Andrew K. W. Powell, Esq. has joined BioLeap's Board of Directors.

Andrew is broadly recognized in the pharmaceutical industry as a senior executive with extensive experience in corporate governance and in structuring and implementing significant merger/acquisition events. "BioLeap is fortunate to have Andrew's active involvement as we continue to grow the company. His broad industry experience coupled with his deep expertise in the areas of structuring collaborations, investments and M&A activities will prove invaluable", commented John Kulp, CEO of BioLeap. "I am excited to be assuming this important role as BioLeap prepares to enhance its service offerings and advance its development programs" said Powell.

Andrew has over 20 years of leadership experience in the pharmaceutical industry with both domestic and international assignments. Most recently he served as Senior Vice President, General Counsel, Secretary for ImClone Systems. Prior to ImClone he was the Vice President, General Counsel, Secretary for CollaGenex Pharmaceuticals. Earlier in his career Andrew spent a number of years at Baxter international with his final assignment being Vice President, Associate General Counsel, Baxter Bioscience.

Andrew received his BA from the University of North Carolina and his Juris Doctor from Stanford University.

About BioLeap:

BioLeap intends to become the leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable leads for important biological targets. BioLeap has identified initial leads in four collaborative ventures and offers compelling lead identification and optimization services for new partners.

Contact:

Gerry Evans, EVP
BioLeap
215-371-2874
ghe@bioleap.com